Monday, August 1, 2011

Vol. 17, No. 15

TRIGGER
The Twice-Monthly Electronic Newsletter on the Biology of Tissue Factor, Factor VII and TFPI
Vol. 17, No. 15 August 1, 2011
(The next issue will be on August 15, 2011)
__________________________________________________________
TRIGGER is also available by RSS Feed:
http://feeds.feedburner.com/blogspot/glro
and BLOG:
http://trigger-tf7.blogspot.com/
__________________________________________________________
PRODUCT ANNOUNCEMENT

The Staclot VIIa-rTF product from Diagnostica Stago, Inc. (catalog #00281) is a kit for plasma analysis of circulating factor VIIa (FVIIa) by a clotting method. It can be run on any instrument reporting clotting times, and is labeled for research use only, not for use in diagnostic procedures worldwide.

This unique product is useful for the determination of FVIIa levels in various disease states such as liver disease (1) and combined hyperlipidemia (2) due to the fact that it reflects coagulation activation as a result of in vivo FVIIa production. Specifically, Staclot VIIa-rTF measurements correlated with liver disease stage (1), degree of lipemia (2) and age (3). In addition, specific determinants of genotype specific FVII levels, such as oral contraception have been analyzed (4). NovoSeven® levels in hemophilia research subjects can also be examined (5-6). Further, Staclot VIIa-rTF was a reliable method for analyzing FVIIa levels in patients given low doses of NovoSeven® (6).

For more information, please contact Paul Riley, PhD; 973-631-1200 x4238, (paul DOT riley AT stago-us DOT com).
  1. E. Rodriguez-Inigo et al., Blood Coagul Fibrinolysis 12, 193 (Apr, 2001).
  2. A. Nordoy, B. Svensson, J. B. Hansen, J Thromb Haemost 1, 690 (Apr, 2003).
  3. G. Mariani et al., Haematologica 84, 620 (Jul, 1999).
  4. G. Mariani, J. Conard, R. M. Bertina, V. Garcia, et al., Arterioscler Thromb Vasc Biol 19, 2024(1999).
  5. G. T. Gerotziafas et al., Br J Haematol 117, 705 (Jun, 2002).
  6. M. Johannessen, G. Nielsen, O. Nordfang, Blood Coagul Fibrinolysis 11 Suppl 1, S159 (Apr, 2000).
DISCLAIMER: Commercial product announcements appearing in TRIGGER are provided "as is" for informational purposes only. The editors of TRIGGER have not necessarily evaluated any materials from commercial suppliers described in this newsletter or on its web sites, and we certainly are not endorsing any specific suppliers or products. Furthermore, the editors receive no revenues from any source in the course of publishing TRIGGER.
__________________________________________________________
PAPERS IN PRESS
AUTHORS: Napoleone E, Cutrone A, Cugino D, Latella MC, Zurlo F, Iacoviello L, de Gaetano G, Donati MB, Lorenzet R.
TITLE: Leptin upregulates tissue factor expression in human breast cancer MCF-7 cells
JOURNAL: Thrombosis Research
ABSTRACT: Introduction: Obesity is a risk factor for both cardiovascular disease and cancer development. Leptin, a cytokine produced by adipose tissue, controls different processes in peripheral tissues, including cancer development and thrombotic disorders in patients with a variety of clinical disorders. Tissue factor (TF), the trigger of blood clotting, is abundant in the adipose tissue.
Since TF, often expressed by cancer cells, is considered a hallmark of cancer progression, we investigated whether leptin could modulate TF in the human metastatic breast carcinoma cell line MCF-7.
Materials and Methods: MCF-7 cells were incubated with or without the different reagents at 37°C. At the end of incubation, cells were tested for procoagulant activity by a one-stage clotting assay, TF and TNF- antigen levels and mRNA by ELISA and real-time RT-PCR, respectively. Leptin receptor was studied by FACS.
Results: Both TF activity and antigen constitutively expressed by MCF-7 were significantly increased by leptin in a dose-dependent fashion. TF mRNA levels were also enhanced indicating that leptin exerts its effect at the transcription level. The effect of leptin was specific and required binding to its receptor (Ob-R), which was found on the surface of the cells, since antibodies against leptin and Ob-R completely prevented TF expression upregulation.
In addition, leptin enhanced both TNF- mRNA synthesis and secretion from MCF7. An anti-TNF- MoAb completely abolished the leptin-induced TF expression.
Conclusions: These data support the hypothesis that leptin, by its upregulation of TF, possibly mediated by TNF- synthesis, may contribute to processes underlying both cancer and vascular cell disorders.

SUBMITTED BY: Dr. Roberto Lorenzet: roberto DOT lorenzet AT rm DOT unicatt DOT it
__________________________________________________________
RECENT PUBLICATIONS ON TISSUE FACTOR, FACTOR VII, AND TFPI
Papers are culled from NLM MedLine (PubMed). Titles in square brackets indicate that the paper was not published in English. References that lack volume or page numbers are typically electronic pre-publications (E-pubs) ahead of the print publication; if so, the final citation with volume and page numbers may or may not appear in a future issue of Trigger.
THE FOLLOWING LINK WILL TAKE YOU TO THE ENTIRE LIST OF THIS ISSUE'S PUBLICATIONS IN A PUBMED "COLLECTION":
http://www.ncbi.nlm.nih.gov/sites/myncbi/collections/public/1ngfxm5CxmdaJsicqVdPhrS/

Boles JC, Williams JC, Hollingsworth RM, Wang JG, Glover SL, Owens AP, 3rd, . . . Mackman N (2011) Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity. Thromb Res.
http://www.ncbi.nlm.nih.gov/pubmed/21762960

Ensley AE, Nerem RM, Anderson DE, Hanson SR, Hinds MT (2011) Fluid Shear Stress Alters the Coagulation Potential of Endothelial Outgrowth Cells. Tissue Eng Part A.
http://www.ncbi.nlm.nih.gov/pubmed/21787250

Ganguly K, Upadhyay S, Irmler M, Takenaka S, Pukelsheim K, Beckers J, . . . Schulz H (2011) Impaired resolution of inflammatory response in the lungs of JF1/Msf mice following carbon nanoparticle instillation. Respir Res 12:94.
http://www.ncbi.nlm.nih.gov/pubmed/21756372

Hemmeryckx B, Van Hove CE, Fransen P, Emmerechts J, Kauskot A, Bult H, . . . Hoylaerts MF (2011) Progression of the Prothrombotic State in Aging Bmal1-Deficient Mice. Arterioscler Thromb Vasc Biol.
http://www.ncbi.nlm.nih.gov/pubmed/21799179

Horowitz NA, Blevins EA, Miller WM, Perry AR, Talmage KE, Mullins ES, . . . Palumbo JS (2011) Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood.
http://www.ncbi.nlm.nih.gov/pubmed/21788337

Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR (2011) A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg 254:194-200.
http://www.ncbi.nlm.nih.gov/pubmed/21772125

Jordan SW, Chaikof EL (2011) Simulated surface-induced thrombin generation in a flow field. Biophys J 101:276-286.
http://www.ncbi.nlm.nih.gov/pubmed/21767479

Karkouti K, Levy JH (2011) Recombinant Activated Factor VII: The Controversial Conundrum Regarding Its Off-Label Use. Anesth Analg.
http://www.ncbi.nlm.nih.gov/pubmed/21788315

Langer F, Bokemeyer C (2011) Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor. Hamostaseologie 31.
http://www.ncbi.nlm.nih.gov/pubmed/21792469

Le Noel A, Merat S, Ausset S, De Rudnicki S, Mion G (2011) [The damage control resuscitation concept.]. Ann Fr Anesth Reanim.
http://www.ncbi.nlm.nih.gov/pubmed/21764247

Lima LG, Oliveira AS, Campos LC, Bonamino M, Chammas R, Werneck C, . . . Monteiro RQ (2011) Malignant transformation in melanocytes is associated with increased production of procoagulant microvesicles. Thromb Haemost 106.
http://www.ncbi.nlm.nih.gov/pubmed/21800005

Moertl D, Berger R, Hammer A, Hutuleac R, Koppensteiner R, Kopp CW, Steiner S (2011) Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure. Thromb Haemost 106.
http://www.ncbi.nlm.nih.gov/pubmed/21800004

Nie XM, Zhou YJ, Li YF, Xie Y, Su LX (2011) [Effects of sirolimus upon endothelial thrombotic function of human umbilical vein endothelial cells]. Zhonghua Yi Xue Za Zhi 91:1281-1284.
http://www.ncbi.nlm.nih.gov/pubmed/21756803

Nosari A, Caimi TM, Zilioli V, Molteni A, Mancini V, Morra E (2011) Cerebral Hemorrhage Treated with Novoseven in Acute Promyelocytic Leukemia. Leuk Lymphoma.
http://www.ncbi.nlm.nih.gov/pubmed/21780994

Quezada M, Diaz J, Henriquez S, Bravo ML, Aranda E, Oliva B, . . . Owen GI (2010) 2-methoxyestradiol inhibits progesterone-dependent tissue factor expression and activity in breast cancer cells. Horm Cancer 1:117-126.
http://www.ncbi.nlm.nih.gov/pubmed/21761355

Sorensen B, Dargaud Y, Kenet G, Lusher J, Mumford A, Pipe S, Tiede A (2011) On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII. Haemophilia.
http://www.ncbi.nlm.nih.gov/pubmed/21771206

Svensson KJ, Kucharzewska P, Christianson HC, Skold S, Lofstedt T, Johansson MC, . . . Belting M (2011) Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. Proc Natl Acad Sci U S A.
http://www.ncbi.nlm.nih.gov/pubmed/21788507

Teruel R, Perez-Sanchez C, Corral J, Herranz MT, Perez-Andreu V, Saiz E, . . . Martinez C (2011) Identification of miRNAs as Potential Modulators of Tissue Factor Expression in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. J Thromb Haemost.
http://www.ncbi.nlm.nih.gov/pubmed/21794077

Trompet S, Pons D, Kanse SM, de Craen AJ, Ikram MA, Verschuren JJ, . . . Jukema JW (2011) Factor VII Activating Protease Polymorphism (G534E) Is Associated with Increased Risk for Stroke and Mortality. Stroke Res Treat 2011:424759.
http://www.ncbi.nlm.nih.gov/pubmed/21789270

Tse EY, Cheung WY, Ng KF, Luk KD (2011) Reducing perioperative blood loss and allogeneic blood transfusion in patients undergoing major spine surgery. J Bone Joint Surg Am 93:1268-1277.
http://www.ncbi.nlm.nih.gov/pubmed/21776581

Versteeg HH, Ruf W (2011) Thiol pathways in the regulation of tissue factor prothrombotic activity. Curr Opin Hematol.
http://www.ncbi.nlm.nih.gov/pubmed/21778880

Witting PK, Song C, Hsu K, Hua S, Parry SN, Aran R, . . . Freedman SB (2011) The acute-phase protein serum amyloid A induces endothelial dysfunction that is inhibited by high-density lipoprotein. Free Radic Biol Med.
http://www.ncbi.nlm.nih.gov/pubmed/21784147

Zahra S, Anderson JA, Stirling D, Ludlam CA (2011) Plasma microparticles are not elevated in fresh plasma from patients with gynaecological malignancy - An observational study. Gynecol Oncol.
http://www.ncbi.nlm.nih.gov/pubmed/21777967

Zheng XW, Kudaravalli R, Russell TT, Dimichele DM, Gibb C, Russell JE, . . . Pollak ES (2011) Mutation in the factor VII hepatocyte nuclear factor 4alpha-binding site contributes to factor VII deficiency. Blood Coagul Fibrinolysis.
http://www.ncbi.nlm.nih.gov/pubmed/21760481
__________________________________________________________
ABOUT TRIGGER
TRIGGER is edited by Jim Morrissey and Pierre Neuenschwander, with editorial assistance by Genie Morrissey. It includes Abstracts of Papers in Press, Meeting Announcements, Positions Sought/Available,or any other pertinent item that subscribers may want to share with their colleagues. To submit an item for publication in Trigger, e-mail us. To request or cancel a subscription,or for more information about TRIGGER or the biology of tissue factor and factor VII, visit our web site. You can also contact us by mail: J.H. Morrissey, University of Illinois College of Medicine, 417 Med Sci Bldg MC-714, 506 S. Mathews Ave., Urbana, IL 61801, USA.

DISCLAIMER: TRIGGER is provided "as is" for information purposes only and without warranty of any kind, express or implied. Users shall assume the entire risk as to the accuracy and usefulness of information in TRIGGER. Opinions expressed here are not necessarily those of the editors or their employers. You may share TRIGGER with your scientific colleagues but you are not permitted to use it or its contents for commercial purposes.
__________________________________________________________